Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
Giuseppe Cabibbo(University of Palermo), Calogero Cammà(University of Palermo), Ciro Celsa(Hammersmith Hospital), Anita Busacca(University of Palermo), Giacomo Emanuele Maria Rizzo(University of Palermo), Salvatore Battaglia(University of Palermo), María Reig(Universitat de Barcelona), Marco Enea(University of Palermo), Massimo Attanasio(University of Palermo), Antonio Craxı̀(University of Palermo), Domenica Matranga(University of Palermo)
Cited by 34
Related Papers
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
|Gastroenterology|2016|1.8k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821